Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248683 | 0.85 | ELANE (0.50) | ELANEAPPMEN1KMT2AKDM4E | |
| SCHEMBL4113139 | 0.76 | ELANE (0.43) | ELANEKDM4ESMN1; SMN2L3MBTL1PIM1 | |
| SCHEMBL6379848 | 0.76 | ZAP70 (0.39) | KDM4ESMN1; SMN2PIM1 | |
| SCHEMBL3798154 | 0.76 | ALDH1A1 (0.32) | — | |
| SCHEMBL3219798 | 0.76 | ALDH1A1 (0.35) | — | |
| SCHEMBL3680113 | 0.76 | POLB (0.41) | MEN1KMT2AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL1004805 | 0.75 | KCNH2 (0.55) | ELANEAPPTAAR1SMN1; SMN2 | |
| SCHEMBL10899344 | 0.75 | ALDH1A1 (0.31) | APPACHE | |
| SCHEMBL3407144 | 0.73 | HRH3 (0.50) | MEN1KMT2APIM1 | |
| SCHEMBL29509040 | 0.73 | TLR8 (0.49) | ELANESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2992883-B1 | PHARMACEUTICAL USE OF HEXAHYDRO-DIBENZO[A,G]QUINOLIZINE COMPOUNDS | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2024-04-24 | — | — | EP | disclosed |
| US-9737517-B2 | Pharmaceutical use of hexahydro-dibenzo[a,g]quinolizine compounds | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-08-22 | — | — | US | disclosed |
| US-20160193195-A1 | PHARMACEUTICAL USE OF HEXAHYDRO-DIBENZO[A,G]QUINOLIZINE COMPOUNDS | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2016-07-07 | — | — | US | disclosed |
| EP-2992883-A1 | PHARMACEUTICAL USE OF HEXAHYDRO-DIBENZO[A,G]QUINOLIZINE COMPOUNDS | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2016-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193195-A1 | PHARMACEUTICAL USE OF HEXAHYDRO-DIBENZO[A,G]QUINOLIZINE COMPOUNDS | BPHL, QDPR, NQO2 | ELANE 2077/4885APP 2761/4885MEN1 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.